Bifogade filer
Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Nanoform Finland Plc | Company Release | January 29, 2026 at 19:00:00 EET
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”) has, on January 29th, 2026, received a notification from Mandatum Oyj in accordance with chapter 9, section 10 of the Securities Market Act. According to the notification, Mandatum Oyj holdings in Nanoform Finland Plc has decreased from 6.56% to 5.96% and within these holdings Mandatum Henkivakuutusosakeyhtiö’s holding in Nanoform Finland Plc has decreased below the level of 5%.
Nanoform has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date of the notification received by Nanoform.
| Total positions of Mandatum Oyj subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached (January 28, 2026) | 5,96% | 5,96% | 85 669 853 | |
| Position of previous notification | 6,56% | 6,56% | ||
A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000330972 | - | 5 106 843 | - | 5,96% |
| SUBTOTAL A | 5 106 843 | 5,96% | ||
B: Financial Instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise/ Conversion Pe-riod | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| - | - | - | - | - | - |
| Total B | - | - |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
| 8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| Mandatum Oyj | - | - | - |
| Mandatum Henkiva-kuutusosakeyhtiö | Under 5% | - | Under 5% |
| Mandatum Asset Management Oy | - | - | - |
| Mandatum Fund Management S.A. | - | - | - |
| Mandatum SICAV UCITS – Mandatum Nordic Active Owner-ship Equity Fund | Under 5% | - | Under 5% |
| 9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of - | |||
| 10. Additional information: Mandatum Henkivakuutusosakeyhtiö holding in Nanoform Finland has decreased below 5% | |||
Notifications of major shareholdings and monthly ownership data can be found on the Company’s website www.nanoform.com.
For further information, please contact:
Peter Hänninen
General Counsel
peter.hanninen@nanoform.com
+358 50 353 0408
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.